98 results about "Partially saturated" patented technology

Described is a method for making a composition comprising alkanes. The composition is suitable for use as a liquid transportation fuel in general, and jet fuel in particular. The method includes dehydrating a feedstock solution comprising a carbohydrate, in the presence of an acid catalyst, to yield at least one furan derivative compound, in a reaction vessel containing a biphasic reaction medium: an aqueous reaction solution and a substantially immiscible organic extraction solution. The furan derivative compound is then subjected to a self-aldol condensation reaction or a crossed-aldol condensation reaction with another carbonyl compound to yield a beta-hydroxy carbonyl compound and / or an alpha-beta unsaturated carbonyl compound. The beta-hydroxy carbonyl and / or alpha-beta unsaturated compounds are then hydrogenated to yield a saturated or partially saturated compound, followed by hydrodeoxygenation (e.g., dehydrating and hydrogenating) of the saturated or partially saturated compound to yield a composition of matter comprising alkanes.

A method is provided for operating a gas turbine plant, in which compressed air is extracted from a compressor and for cooling is directed in an internal cooling passage through thermally loaded components to the combustion chamber and / or to the turbine, then re-cooled, and added to the compressor main flow in the compressor. At least a portion of the recirculated air is supersaturated, or partially saturated, with drops of water during or before recirculation into the compressor and a cooling mist is created. A gas turbine plant is provided with a closed cooling circuit which, for implementing the method, includes an injection arrangement for introducing water into the recirculated cooling air.

The present invention provides a novel compound having an excellent PPAR agonist action. More specifically, it provides a compound represented by the following formula, a salt thereof, an ester thereof or a hydrate of them. Wherein a, b and c are the same as or different from one another and each represents 0 to 4; R1 to R6 are the same as or different from one another and each represents a hydrogen atom, a hydroxyl group, a cyano group, a halogen atom, etc.; A1 and A2 are the same as or different from each other and each represents a single bond, an oxygen atom, etc.; L, M and T each represent a single bond, an alkylene group having one to six carbon atoms, etc.; W represents a carboxyl group; the partial structure represented by the formula:  represents a single bond or a double bond; X represents a single bond, an oxygen atom, —NRX1CQ1O—, etc.; Y represents Y1—Y2— (wherein Y1 represents a 5 to 14-membered aromatic ring having one to four substituents, etc.; and Y2 represents a single bond or a 5 to 14-membered aromatic ring); and the ring Z represents a 5 to 14-membered aromatic ring which have one to four substituents selected form the above-mentioned Group A, may have one or more hetero atoms and may be partially saturated.

A compound of the formula:or a pharmaceutically acceptable salt thereof, whereinR1 and R2 are independently selected from hydrogen, halo, hydroxy, (C1-C4)alkyl, halo (C1-C4)alkyl and the like; R3 and R4 are independently selected from hydrogen, halo(C1-C10)alkyl, optionally substituted (C1-C6)alkyl and the like, or R3 and R4, together with the nitrogen atom to which they are attached, form an optionally substituted fully saturated, partially saturated or fully unsaturated heterocyclic ring; and R5 is (C4-C11)cycloalkyl and the like, has ORL1-receptor agonist activity, and are useful as analgesics or the like in mammalian subjects.

Improved sensors and sensing methods for detection of Neuromuscular Blockade (NMB), for example to improve monitoring generally, as well as facilitate automated NMB drug administration. The methods, systems, devices, etc., herein can increase the quantity and quality of data available. The methods, etc., include translation between commonly available sensing types, use of partially saturated sensor measurements, use of a model of neurotransmitter storage and release and sophisticated use of more than one sensor simultaneously. These methods are aided by new sensors and methods of decreasing electrical noise. An implementation of the methods, systems, devices, etc., herein is automated drug delivery for NMB, whether through an advisor system or through with full computer control.

A magnetometer (100) for measuring an external magnetic field has at least one core (102), two excitation coils (106a), (106b), and a pick-up coil (104). The at least one core (102) has a magnetoresistance property measurable in response to the external magnetic field (111). Each excitation coil (106a), (106b) is near or around opposite ends of the core (102) or near or around a respective core. The excitation coils (106a), (106b) are configured to be driven by an alternating current to partially saturate a magnetisation of the core during part of the AC cycle. The pick-up coil (104) is near or around at least a portion of the core (102) and the excitation coils (106a), (106b). The pick-up coil (104) is configured to carry a signal induced at least in the presence of the external magnetic field (111). The induced signal is measurable in response to the external magnetic field (111).

The invention provides compounds of the formula: wherein R1 is aryl, heteroaryl, cycloalkyl or alkyl; R2 is H, alkyl, nitro, C02R7, CONR5R6 or halo; R3 and R4 are H, NR5R6, NC(O)R7, halo, trifluromethyl, alkyl, CONR5R6, CO2R7, nitrile or alkoxy; R5 and R6 may be the same or different and may be H, alkyl, aryl, heteroaryl or cycloalkyl; or R5 and R6 may together form a saturated, unsaturated or partially saturated 4 to 7 member ring, wherein said ring may optionally comprise one or more further heteroatoms selected from N, O or S; R7 is H or alkyl; A is H, halo, or a group of formula X-L-Y; X is O, S or NR8; R8 is H or alkyl; L is (CH2)n, where n is 0, 1, 2, 3 or 4; and Y is aryl, a heterocyclic group, alkyl, alkenyl or cycloalkyl; the products of mono- and di-oxidation of sulphur and / or mono-oxidation of nitrogen moieties in compounds of formula I; or a pharmaceutically acceptable salt thereof. These compounds find use as inhibitors of potassium ion channels and thus are useful in the treatment of various conditions including arrhythmia and type-2 diabetes mellitus.

This invention provides caspase inhibitors having the formula:wherein Ring A is an optionally substituted piperidine, tetrahydroquinoline or tetrahydroisoquinoline ring; R1 is hydrogen, CHN2, R, or —CH2Y; R is an optionally substituted group selected from an aliphatic group, an aryl group, an aralkyl group, a heterocyclic group, or an heterocyclylalkyl group; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; Ar is an optionally substituted aryl group; and R3 is hydrogen, an optionally substituted C1-6 alkyl, F2, CN, aryl or R3 is attached to Ar to form an unsaturated or partially saturated five or six membered fused ring having 0–2 heteroatoms. The compounds are useful for treating caspase-mediated diseases in mammals.

A low viscosity polymer having a linear or branched backbone derived from farnesene monomers and at least one terminal-end functionalized with a hydroxyl group. This polymer may be further hydrogenated to reduce unsaturation and acrylated, such that it may be incorporated into a LOCA composition. The LOCA composition may be used in a laminated screen assembly, such as a touch screen, for electronic devices by adhering the LOCA composition between an optically transparent layer, such as a cover glass, and a display. The cured LOCA composition has a refractive index similar to the optically transparent layer. A method of making the low viscosity polymer for the LOCA composition includes anionically polymerizing farnesene monomers, quenching a living end of the polymer to provide the hydroxyl-terminated polymer; hydrogenating the hydroxyl-terminated polymer; and reacting the at least partially saturated hydroxyl-terminated polymer with at least one reagent to provide an acrylate terminated hydrogenated polymer.

The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc. The symbols in the formula represent the following meanings: Ar: optionally substituted aryl or optionally substituted heteroaryl here, the cyclic portion of the heteroaryl is bicyclic heterocyclic ring in which 5- to 6-membered monocyclic heterocyclic ring containing 1 or 2 hetero atom(s) and benzene ring are fused; R1: a group selected from the group consisting of optionally substituted cyclic hydrocarbon group, and optionally substituted heterocyclic group; n: an integer of 1 to 3; X: single bonding arm, —CH2—, —CO—, —(CH2)m—CO—, —CH(R2)—CO—, —(CH2)p—Y—(C(R3)(R4))q—CO—, —NH—CO— or —N(R5)—CO—; in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R1; m is an integer of 1 to 3; p is an integer of 0 to 2; q is an integer of 0 to 2; Y: —O— or —SO2—; R2: phenyl or lower alkyl; R3, R4: each independently represents hydrogen atom or lower alkyl; R5: lower alkyl; provided that the ring portion of the group represented by R1 is neither naphthylidine nor partially saturated group thereof, and, when X is —CH2— or —CO—, R1 is not naphthyl.

An apparatus for detecting output power from an amplifier (103) comprises a first controller (105) for controlling output power of a signal from the amplifier (103), a device (107) for measuring dc bias current / voltage at an output (115) of the amplifier (103), second controller (109) operative to set the first controller (105) to a setting corresponding to an output power at a finite level, and a detector (109) for determining whether or not there is output power from the amplifier based on the measured dc bias current / voltage at the setting of the first controller (105). In one embodiment, the first controller (105) is set at a setting corresponding to an output power level which is sufficient to at least partially saturate the amplifier (103).

The invention discloses a method for correcting response inconsistency of linear array CCD (Charge Coupled Device) image elements. According to the characteristics of a CCD, the existing two-point flat field correction method is improved based on correct calculation of dark current noise; and based on formation mechanism of response inconsistency of the image elements, an inconsistency correctionmethod is divided into two independent parts (dark current noise and inconsistency correction and photoelectric response inconsistency correction), and digital gain correction is also introduced, finally, the correction of response inconsistency of the linear array CCD image elements is implemented. The method provided by the invention can be used for overcoming the defect that, in a two-point correction method, values of dark image elements cannot correctly reflect present dark current noise when the CCD is partially saturated; and the method can be widely used in the present imaging devices, has the characteristics of being easy to realize and high in precision, and can be used for eliminating image degradation caused by dark current noise and image element response inconsistency noise and improving the imaging performance of a detector.

A disinfecting cleaning wipe of stitch-bonded construction. The wipe includes a stitching substrate of fibrous nonwoven material having a mass per unit area of not more than 30 grams per square meter. A first plurality of stitching yarns is disposed in stitched relation through the stitching substrate in a pattern of substantially parallel linear stitch lines extending in a first direction across the stitching substrate. At least a second plurality of stitching yarns is disposed in stitched relation through the stitching substrate in a repeating zigzag pattern to define a first group of surface yarn float segments extending diagonally between stitch positions at opposing linear stitch lines. A disinfecting solution at least partially saturates the cleaning wipe.

This invention relates to a method of producing aromatics and light paraffins from hydrocarbonaceous oils derived from oil, coal or wood, including partially saturating and hydrocracking the oils derived from oil in a hydrogenation and reaction area, separating them depending on the number of carbons, recirculating heavy oils having 11 or more carbons to the hydrogenation and reaction area, feeding oils suitable for producing BTX to an aromatic separation process and a transalkylation process to recover aromatics, and feeding hydrocarbonaceous components having 5 or fewer carbons to a light separation process, thus obtaining light paraffins.

A lubricating composition comprising a major amount of base oil and a minor amount of an additive package, wherein the additive package comprises: (A) a friction modifier component selected from: (a) one or more a reaction products of an alcohol with a compound of the formula IV: (see formula IV); and (b) one or more compounds of the Formulae II-III: (see formula II) (see formula III) wherein wherein R is a linear or branched, saturated, unsaturated, or partially saturated hydrocarbyl having about 8 to about 22 carbon atoms; R2 and R3 are independently selected from hydrogen, C1-C18 hydrocarbyl groups, and C1-C18 hydrocarbyl groups containing one or more heteroatoms; and X is an alkali metal, alkaline earth metal, or ammonium cation and n is the valence of cation X; and (B) at least one metal dialkyl dithio phosphate salt.

The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins. In the compounds of this invention, at least two carbo- or heterocyclic groups are attached to a central saturated, partially saturated, or aromatic 5-6 membered carbocyclic ring by a combination of straight or branched linker chains. The invention further relates to pharmaceutical compositions comprising one or more of the said compounds, and to the uses of these compounds and compositions for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity, and for research, development, and therapeutic applications in a variety of medical disorders, such as neurological disorders, hair loss disorders, ischemic disorders, and disorders caused by viral or protozoan infection.

A drier apparatus for removing water from various materials includes a drying chamber, a regenerator system, a drying fluid system, and a heating fluid recirculation system and a method for use of the apparatus. The material to be dried flows concurrently through the drier with a heating fluid that is segregated from the material but in heat transfer relationship with the material. A drying fluid flows countercurrent through the chamber so as to become heated and at least partially saturated from moisture released by the material. The drying fluid is then used to preheat recycled heating fluid which is further heated by a makeup heater. In some embodiments, the drying fluid is also recycled to the chamber after passing through a chiller.

The present invention provides a production method of oxo fatty acid, as well as rare fatty acids such as conjugated fatty acid, hydroxylated fatty acid, partially saturated fatty acid and the like, which uses 4 kinds of enzymes (fatty acid-hydratase, hydroxylated fatty acid-dehydrogenase, oxo fatty acid-isomerase, oxo fatty acid-enone reductase) derived from Lactobacillus plantarum including lactic acid bacteria and the like. Furthermore, the present invention also provides a more efficient production method of oxo fatty acid and the like, which partly uses a chemical oxidation reaction in combination.

Diraromatic amine derivatives having the general formula: wherein n is from 0 to 5; m is from 0 to 4; each R substituent is independently hydrogen or a straight or branched C1-C32 alkyl group or alkenyl group or two R substituents together with the carbon atom to which they are bonded are joined together to form an unsaturated, partially saturated or saturated C3-C30 ring structure optionally containing one or more heteroatoms, each R1 substituent is independently hydrogen or a straight or branched C1-C32 alkyl group or alkenyl group and R2, R3, R4, R5, R6 and R7 are independently hydrogen or a straight or branched C1-C32 alkyl group or alkenyl group optionally containing a functional group are provided. Also provided are lubricating oil compositions containing the diraromatic amine derivatives.

The present invention relates to a method for the catalytic removal of carbon dioxide and NOx from waste gases in a reactor charged with activated carbon catalyst. The method comprises the following steps:a. saturating the catalyst with waterb. saturating or partially saturating the waste gases with water,c. introducing the waste gases into the reactor,d. catalytically converting NOx into NO2− and, in parallel with this, catalytically converting CO2 into carbon and O2 on the same catalyst,e. washing out the activated carbon catalyst with water and discharging the carbon as a solid and NO2— dissolved in water or in the base.

A method for measuring the partially saturated fluid transport properties of an absorbent. The steps of the method are generating a physical spatial map of saturation of a fluid within an absorbent in a physical test environment, generating a virtual spatial map of saturation of a fluid within an absorbent in a virtual test environment, and identifying the absorbent-fluid interaction properties for the absorbent such that the virtual spatial map of saturation approximates the physical spatial map of saturation.

A method and apparatus for separating arsenic from an aqueous solution containing arsenic. The method includes the steps of contacting an arsenic-containing solution with a first portion of fixing agent to remove at least a portion of the arsenic. An arsenic-laden fixing agent is separated from the solution and the partially depleted solution is contacted with a second portion of fixing agent. The fixing agent can include a high surface area insoluble compound containing one or more of cerium, lanthanum, or praseodymium. Following removal of the arsenic, the arsenic-depleted solution can be further processed to separate a recoverable metal through metal refining. The arsenic-laden fixing agent can be filtered to recover and recycle a filtrate to the solution for additional treatment, as well as using a partially saturated fixing agent to remove arsenic from fresh solution. An arsenic-containing solution can be formed from arsenic-containing solids such as contaminated soils, industrial byproducts and waste materials.

The present invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts, wherein ring “Ar1” represents a monocyclic or polycyclic aromatic or partially saturated aromatic polycyclic, which may optionally contain up to 3 heteroatoms selected from N, S or O. The said monocyclic or polycyclic ring may be unsubstituted or have up to 4 substituents which may be identical or different; m and n independently represents an integer from 0 to 6; A represents O, S or bond; Y is selected from (CH2)p′(CH2)pB(CH2)q′(CH2)rB(CH2)pD(CH2)p′ where p, q and r each independently represents an integer from 0 to 6; B and D independently represents S, O, NR4 or a bond, with a proviso that when B and D represents hereto atom p is not zero; R4 represents hydrogen, alkyl, alkenyl, —S(O)2—R8 or —C(O)R8 where R8 is alkyl, alkoxy; R5 and R6 independently represents hydrogen, alkyl, cycloalkyl or alkoxy; R5 and R6 together may form 3-8 membered cyclic ring which may optionally contains one or two hereto atoms selected from O, S or N; R7 represents hydrogen, optionally substituted groups selected form alkyl, cycloalkyl, alkenyl or alkynyl. The present invention also relates to a process for preparation of compounds of formula (I), to pharmaceutical compositions containing compounds of formula (I) and their use in particular as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic agents.